Ruane Peter J, DeJesus Edwin
J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S21-9. doi: 10.1097/01.qai.0000137003.25258.76.
The nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) class continues to serve as an important component of the standard of care for HIV infection. Combinations of dual NRTIs/NtRTIs with protease inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs) remain the most commonly used regimens in clinical practice. In recent years, clinical outcomes data on previously novel NRTI/NtRTI backbone combinations have provided clinicians with new options to address potency, tolerability, and convenience of antiretroviral therapy. However, the tolerability, drug-drug interactions, and resistance profiles of specific regimens using new NRTI/NtRTI combinations must be weighed against the needs and preferences of individual patients. This review summarizes recent efficacy and safety data on emerging NRTI/NtRTI combination backbones, including tenofovir DF (TDF) with lamivudine (3TC), abacavir with 3TC, didanosine (ddI) with 3TC, ddI with emtricitabine (FTC), and TDF with FTC.
核苷/核苷酸逆转录酶抑制剂（NRTI/NtRTI）类药物仍然是治疗HIV感染标准治疗方案的重要组成部分。双NRTI/NtRTI与蛋白酶抑制剂（PI）或非核苷逆转录酶抑制剂（NNRTI）的联合用药仍然是临床实践中最常用的治疗方案。近年来，关于以前新型NRTI/NtRTI主干联合用药的临床疗效数据为临床医生提供了新的选择，以解决抗逆转录病毒治疗的效力、耐受性和便利性问题。然而，使用新的NRTI/NtRTI联合用药的特定治疗方案的耐受性、药物相互作用和耐药性情况必须根据个体患者的需求和偏好进行权衡。本综述总结了新兴的NRTI/NtRTI联合主干用药的近期疗效和安全性数据，包括替诺福韦酯（TDF）与拉米夫定（3TC）、阿巴卡韦与3TC、去羟肌苷（ddI）与3TC、ddI与恩曲他滨（FTC）以及TDF与FTC。
